In contrast, while both EBM and RuleFit predominantly select non-enzyme genes (95%), these genes, such as SMIM2 antisense RNA 1, are not notably linked to tumor hallmarks, unlike the feature genes identified by our framework (Table S7). Here, LINC00390 is linked to neoplasm.